Researchers at the UCLA Health Jonsson Comprehensive Cancer Center have developed a new platform that combines 3D bioprinting ...
Unlike accidental cell death, some cells can actively decide to die through a controlled process. This is called programmed ...
Researchers developed a platform combining 3D bioprinting, imaging and AI to monitor drug responses in tumor organoids. It ...
Efforts to identify and evaluate next-generation therapeutics for pediatric brain tumors are easily stymied by the quality and availability of laboratory models for research. To address this issue, ...
Researchers at the UCLA Health Jonsson Comprehensive Cancer Center have developed a new platform that combines 3D bioprinting, advanced imaging and artificial intelligence to better monitor how cancer ...
NEW YORK--(BUSINESS WIRE)--Signet Therapeutics (“Signet”), a clinical-stage biotech company leveraging organoids and AI to develop first-in-class cancer therapies, today announced that the first ...
NewYork-Presbyterian's GLICO seeks to overcome glioblastoma's resistance by mimicking brain environments to test treatments ...
For the first time, researchers used lab-grown organoids created from tumors of individuals with glioblastoma (GBM) to accurately model a patient's response to CAR T cell therapy in real time. The ...
Agreement Marks Company’s Expansion into Precision Oncology Testing, with the Goal of Establishing Malaysia's First ...
Patient-derived glioblastoma organoid treated with dual-target CAR-T cells. T cells (magenta) infiltrate the tumor organoid and kill tumor cells (blue) (yellow indicates dying cells). PHILADELPHIA— ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results